Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Gold

Showing results (41-50 of 700) with videos related to

Pageof 70
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2022
Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosisJeremias Motte, Ralf Gold
Therapeutic Advances in Neurological Disorders|October 11, 2019
Progressive multiple sclerosis: latest therapeutic developments and future directionsSimon Faissner, Ralf Gold
Journal of Neurology|June 8, 2011
Progressive multifocal leukoencephalopathy and natalizumabKerstin Hellwig, Ralf Gold
The American Journal of Pathology|December 8, 2007
Interleukin-17--extended features of a key player in multiple sclerosisRalf Gold, Fred Lühder
Journal of Neurology|January 9, 2004
Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatmentAntonios Bayas, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 28, 2017
Dimethyl fumarate for patients with neuromyelitis optica spectrum disorderKalliopi Pitarokoili, Ralf Gold
Experimental Neurology|April 14, 2009
Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?Aiden Haghikia, Ralf Gold
Journal of Neurology|May 16, 2007
Neuropsychological/-psychiatric deficits in immune-mediated neuropathiesAndrew Chan, Ralf Gold
Nature Reviews. Neurology|March 19, 2014
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MSAiden Haghikia, Ralf Gold
Neurology|April 23, 2003
The pathogenesis of CIDP: rationale for treatment with immunomodulatory agentsKlaus V Toyka, Ralf Gold
Pageof 70

Showing results (41-50 of 700) with videos related to

Sort By:
Pageof 70
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2022
Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosisJeremias Motte, Ralf Gold
Therapeutic Advances in Neurological Disorders|October 11, 2019
Progressive multiple sclerosis: latest therapeutic developments and future directionsSimon Faissner, Ralf Gold
Journal of Neurology|June 8, 2011
Progressive multifocal leukoencephalopathy and natalizumabKerstin Hellwig, Ralf Gold
The American Journal of Pathology|December 8, 2007
Interleukin-17--extended features of a key player in multiple sclerosisRalf Gold, Fred Lühder
Journal of Neurology|January 9, 2004
Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatmentAntonios Bayas, Ralf Gold
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 28, 2017
Dimethyl fumarate for patients with neuromyelitis optica spectrum disorderKalliopi Pitarokoili, Ralf Gold
Experimental Neurology|April 14, 2009
Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?Aiden Haghikia, Ralf Gold
Journal of Neurology|May 16, 2007
Neuropsychological/-psychiatric deficits in immune-mediated neuropathiesAndrew Chan, Ralf Gold
Nature Reviews. Neurology|March 19, 2014
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MSAiden Haghikia, Ralf Gold
Neurology|April 23, 2003
The pathogenesis of CIDP: rationale for treatment with immunomodulatory agentsKlaus V Toyka, Ralf Gold
Pageof 70